Ipamorelin vs CJC-1295 (No DAC): Mechanism, Half-Life & Research Use

Direct Comparison: Key Differences at a Glance

In preclinical models evaluating ipamorelin vs cjc-1295 (no dac), key differences center on receptor targets and signal kinetics. Ipamorelin selectively targets the ghrelin/growth hormone secretagogue receptor (GHS-R1a) with minimal cortisol or prolactin release. Conversely, CJC-1295 (No DAC) acts as a GHRH analog, binding the GHRH receptor to stimulate endogenous somatotropin synthesis and sustain downstream IGF-1 levels for tissue repair research.

Because these two compounds engage separate signaling cascades within the somatotropic axis, researchers often evaluate them individually or in combined in vitro and animal models to observe potential synergistic GH secretion profiles. Selectivity, half-life, and receptor desensitization thresholds differ significantly between the two classes, making precise compound selection essential for reliable research outcomes.

Comparative Overview Table & Biochemical Parameters

To evaluate how these research compounds behave in laboratory assays, scientists compare specific physicochemical and pharmacological parameters. Below is a structured analysis of the primary criteria governing Ipamorelin and CJC-1295 (No DAC) in empirical research environments:

• Primary Receptor Target: Ipamorelin targets the Growth Hormone Secretagogue Receptor (GHS-R1a / Ghrelin Receptor); CJC-1295 (No DAC) targets the Growth Hormone-Releasing Hormone Receptor (GHRHR). • Mechanistic Class: Ipamorelin is a selective GHRP (Growth Hormone Releasing Peptide) mimetic; CJC-1295 (No DAC) is a synthetic GHRH analog (modified GRF 1-29). • Reported Plasma Half-Life: Ipamorelin exhibits approximately 2 hours in rodent models; CJC-1295 (No DAC) demonstrates a shorter half-life of roughly 30 minutes in vivo. • Primary Endocrine Effect: Ipamorelin triggers amplified GH pulses without elevating adrenocorticotropic hormone (ACTH) or prolactin; CJC-1295 (No DAC) provides sustained GHRH signaling to promote continuous intracellular cAMP production. • Solubility Profile: Both exhibit high aqueous solubility in standard laboratory diluents, including sterile bacteriostatic water or buffered saline solutions (pH 6.0–7.4). • Common Preclinical Models: Rodent metabolic assays, cell culture somatotroph proliferation studies, and non-human primate neuroendocrine evaluations. • Standard Laboratory Vial Sizes Available: High-purity lyophilisates available in standard 2 mg, 5 mg, and 10 mg analytical research vials.

Understanding these baseline characteristics helps research teams select the exact formulation required for their specific analytical setups, whether studying pulse amplitude, receptor down-regulation, or downstream metabolic cascades.

Ipamorelin: Selective Ghrelin Receptor (GHS-R1a) Agonism

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) engineered to bind selectively to the GHS-R1a receptor located on pituitary somatotrophs and hypothalamic neurons. Unlike older growth hormone secretagogues such as GHRP-6 or GHRP-2, preclinical evaluations demonstrate that Ipamorelin stimulates growth hormone release without triggering significant secondary elevations of cortisol, adrenocorticotropic hormone (ACTH), or prolactin.

This high degree of receptor specificity makes Ipamorelin a preferred tool in long-term rodent studies where secondary endocrine disruptions could confound experimental data. In vitro receptor binding assays show that Ipamorelin mimics the native hormone ghrelin, triggering intracellular calcium influx via phospholipase C signaling. As a result, somatotroph cells release concentrated bursts of growth hormone that mirror physiological pulsatility without causing desensitization at standard laboratory concentrations.

CJC-1295 (No DAC): Synthetic GHRH Receptor Agonism

CJC-1295 (No DAC), also known as Modified GRF 1-29, is a 29-amino acid tetrasubstituted peptide analog of human growth hormone-releasing hormone (GHRH). The modifications (Tyr-D-Ala-Asp-Ala at the N-terminus) protect the molecule against rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), extending its biological half-life compared to native GHRH(1-29) or Sermorelin.

Functioning strictly as a GHRH analog, CJC-1295 (No DAC) is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. By binding to GHRH receptors on somatotroph cells, it stimulates adenylyl cyclase, raising intracellular cyclic AMP (cAMP) levels and accelerating GH gene transcription and hormone release. Because it lacks the Drug Affinity Complex (DAC) maleimide group, it avoids permanent binding to serum albumin, allowing researchers to study physiological, transient GHRH receptor signaling without continuous, non-pulsatile elevation.

Preclinical Literature Review: Secretagogue Dynamics in Animal Models

Preclinical studies evaluating secretagogue co-administration suggest that activating both GHS-R1a and GHRH receptor pathways yields a non-linear, synergistic release of growth hormone in animal models. When a GHRH agonist like CJC-1295 (No DAC) binds its receptor, it increases the total intracellular pool of cAMP and readies storage vesicles containing somatotropin. Simultaneously, a GHS-R1a agonist like Ipamorelin triggers protein kinase C pathways and suppresses endogenous somatostatin activity.

In vitro pituitary cell cultures demonstrate that simultaneous exposure to both compound classes results in GH release amplitudes significantly higher than the mathematical sum of either compound administered alone. Comparative animal studies evaluating CJC-1295 (No DAC) side-by-side with ghrelin mimetics confirm that dual-pathway agonism preserves the body's natural pulsatile rhythm while maximizing total circulating levels of insulin-like growth factor 1 (IGF-1) for cellular proliferation and extracellular matrix synthesis assays.

Comparative Class Analysis: GHRH vs GHRP Peptides

To properly categorize these compounds within broader research paradigms, investigators classify them into distinct mechanistic groups. A comprehensive understanding of the secretagogue landscape requires comparing multiple related compounds within the growth axis:

When designing comparative research trials, investigators frequently analyze Ipamorelin against GHRP-6, GHRP-2, and GHRH analogs like CJC-1295 (No DAC) or Sermorelin. While GHRH analogs primarily drive GH synthesis and transcript accumulation, GHRPs facilitate the immediate release of stored vesicles. By selecting the appropriate class—or a combination of both—research teams can precisely tailor secretagogue kinetics to match experimental endpoints in cell culture or animal research.

Selecting the Optimal Compound for Specific Research Designs

Choosing between ipamorelin vs cjc-1295 (no dac) depends heavily on the primary hypothesis and analytical measurements required by the study design:

1. Isolated Pulse Signal Investigations: When isolating the specific impact of GHS-R1a activation without confounding metabolic side-effects or baseline hormone shifts, Ipamorelin is ideal due to its absolute receptor selectivity. 2. Tissue Repair & Matrix Synthesis Models: When investigating collagen deposition, cell differentiation, or downstream organ system repair driven by continuous IGF-1 expression, CJC-1295 (No DAC) serves as the primary GHRH analog of interest. 3. Synergistic Secretagogue Studies: Models evaluating maximal peak somatotropin concentration without high dose toxicity frequently employ both compounds in combination, exploiting dual cAMP and IP3/DAG intracellular cascades. 4. Receptor Desensitization Assays: Researchers analyzing long-term receptor dynamics prefer CJC-1295 (No DAC) due to its shorter, transient half-life that prevents chronic receptor down-regulation when pulsed intermittently.

Laboratory Handling, Reconstitution, and Storage Protocols

Both Ipamorelin and CJC-1295 (No DAC) are supplied as lyophilized (freeze-dried) cakes to ensure long-term stability during shipping and storage. Reconstitution must be performed under sterile laboratory conditions using appropriate solvent media, such as 0.9% bacteriostatic sodium chloride or sterile water for injection.

Prior to reconstitution, researchers should consult the PX1 Research reconstitution calculator to determine precise solvent volumes and concentration ratios for accurate micro-pipetting. Lyophilized vials should be stored at -20°C for long-term preservation. Once reconstituted, solutions should be kept at 2°C to 8°C and used within an experimental window that minimizes peptide hydrolysis or aggregation.

To explore our complete inventory of analytical-grade secretagogues and specialized synthesis options, browse all peptides offered for specialized laboratory research.

Quality Verification: Analytical Testing and COA Standards

Reliable scientific outcomes require research compounds manufactured under rigid quality controls. PX1 Research ensures that every lot of Ipamorelin and CJC-1295 (No DAC) undergoes rigorous analytical verification before distribution to academic, biotechnology, and institutional laboratories.

All materials are manufactured in GMP-compliant facilities within the USA and tested by independent ISO 17025 accredited laboratories. Purity is validated via High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to guarantee a minimum purity threshold of 99%. Additionally, bacterial endotoxin testing (LAL assay) is conducted on every batch to confirm safety for sensitive cellular culture systems and animal research applications. Researchers can independently review batch-specific data by accessing our COA library or contacting our wholesale team for bulk laboratory account parameters.